1. Introduction
===============

The substantial increase in the incidence of type 2 diabetes mellitus (T2DM) (from 8.8% in 1999 to 11.7% in 2014) boost T2DM as one of the leading cause of death or disability all over the world.^\[[@R1],[@R2]\]^ Guidelines of the American Diabetes Association in 2018 recommend metformin as first-line pharmacological therapy for the management of T2DM.^\[[@R3]\]^ The rest of hypoglycemic agents are used as second-line treatment option in whom glycemia control is not achieved with metformin, or unable to tolerate metformin due to gastrointestinal side effects or contraindications, for instance, renal insufficiency.^\[[@R3],[@R4]\]^ Sodium-glucose co-transporter 2 (SGLT2) inhibitors, a neotype oral antidiabetic drugs, lessening blood pressure by reducing renal glucose reabsorption, and causing urinary glucose excretion, provide a new second-line choice for treating T2DM at the same time.^\[[@R3],[@R5],[@R6]\]^ Results from the majority randomized controlled trials (RCTs) published in the last 3 years suggested a favorable overall safety profile of SGLT2 inhibitors. Concerns about SGLT2 inhibitors--related adverse events (AEs) are, however, still accompanied in particularly infection-related effects, osmotic diuresis, ketoacidosis, acute kidney injury, and so on.^\[[@R6]--[@R10]\]^ Furthermore, the Food and Drug Administration (FDA) has issued the warnings about occurrences of urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, bone fracture or bone mineral density, and leg and foot amputations during postmarketing studies of SGLT2 inhibitors.^\[[@R11]--[@R14]\]^ Although SGLT2 inhibitors have been evaluated or currently being evaluated in large-scale, long-term randomized trials and real-world trials, there is still a lack of comprehensive evaluation of its safety issues. Otherwise, inadequate knowledge about comparative risks of SGLT2 inhibitors lead to its prudent use in the treatment of T2DM. In this study, we will conduct a systematic review and meta-analysis to present an overview of the clinical effects events of SGLT2 inhibitors in subjects with T2DM.

2. Methods
==========

2.1. Registration
-----------------

The reporting of the review will follow the principle of Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and conduct following a priori established protocol (PROSPERO: CRD42018090153).^\[[@R15]\]^ Ethical approval is not required because this is a literature-based study.

2.2. Criteria for considering studies for this review
-----------------------------------------------------

This review will include double-blinded, placebo-controlled RCTs irrespective of language. Adult patients with T2DM will be included. The intervention comparisons will constitute SGLT2 inhibitors (dapagliflozin, canagliflozin, empagliflozin, tofogliflozin, luseogliflozin, ipragliflozin, and ertugliflozin) versus placebo. Cointerventions with other antidiabetic agents or comparing with other hypoglycemic agents will be excluded. The duration of these studies should be at least 12 weeks.

2.3. Types of outcome measures
------------------------------

This protocol proposes to assess the overall safety of SGLT2 inhibitors, mainly including AEs varying degrees and AEs occurring in ≥3% patients or AEs aroused concerns by the FDA, such as urinary tract infections, genital tract infections, hypoglycemia, ketoacidosis, acute kidney injury, bone fracture--related effects, total withdrawals, death, and so on.

2.4. Search methods for identification of studies
-------------------------------------------------

We will perform a comprehensive literature search of relevant databases including MEDLINE, EMBASE, Cochrane Library, and the ClinicalTrials.gov Website up to June 2018 to identify all double-blinded RCTs comparing SGLT2 inhibitors with placebo. Briefly, the search terms will include "sodium glucose cotransporter," "SGLT2," "SGLT-2," individual names including trade name and their drug code of SGLT-2 inhibitors, "random" and "RCTs" (Table [1](#T1){ref-type="table"}). Furthermore, we will search for additional eligible trials from the reference lists of other review articles, systematic reviews, and relevant publications. The details of the selection process are shown in Figure [1](#F1){ref-type="fig"}.
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2.5. Data collection and analysis
---------------------------------

Three authors (FHS, HL, and LS) will independently extract data and any disagreements are resolved by consensus or consulting a fourth author (ZCG). Literatures that are not conformed to the established inclusion criteria will be excluded. If the integrality of article is incomplete, we will email to the corresponding or first authors.

2.6. Data extraction
--------------------

Electronic forms will be developed; the substantial contents of each selected articles will be extracted by 3 authors (FHS, HL, and LS), respectively; and the following data will be extracted: the name of the first author; NCT number; publication time; randomization; intervention characteristics such as type, dose, and duration of interventions; and patient characteristics such as background treatment, mean age, proportion of man, duration of type 2 diabetes, body mass index, glycosylated hemoglobin, and any safety data. Any disagreements are resolved by consensus or by consulting a fourth author (ZCG).

2.7. Assessment of risk of bias in included studies
---------------------------------------------------

We will use the *Cochrane Handbook for Systematic Reviews of Interventions* to assess bias risk, which include the following 7 items: randomization, allocation concealment, blinding (including participants and personnel and outcome assessment), incomplete outcome data, selective reporting, and other bias. Furthermore, we will judge these items by low risk, high risk, or unclear risk of bias. Any disagreement will be settled by discussion or consult to the fourth author.

2.8. Statistical analyses
-------------------------

Analyses will be performed by Stata V12.0 (STATA Corp, College Station, TX). Heterogeneity will be assessed by *I*^2^ values. *I*^2^ values \<50% will be considered as acceptable heterogeneity, and \>50% as considerable heterogeneity. When *I*^2^ values \>50%, a random effects model with DerSimonian-Laird method will be used to assess the effect estimates, whereas *I*^2^ values \<50%, a fixed effects model with Mantel-Haenszel method will be used. In addition, we will adopt qualitative description to analyze the data if quantitative synthesis is not appropriate.

2.9. Subgroup analysis
----------------------

We plan to perform subgroup analyses based on different categories and dosages of each SGLT2 inhibitors.

2.10. Sensitivity analysis
--------------------------

We will conduct sensitivity analysis to identify the robustness of the result by omitting each of the study or excluding low-quality trials.

2.11. Reporting biases
----------------------

We plan to perform funnel plots to identify potential reporting biases. In addition, we will also conduct Begg test and Egger test if asymmetry is showed by a visual inspection. There is no significant publication bias when *P* \> .05 in Begg test and Egger test.

2.12. Ethics and dissemination
------------------------------

This systematic review does not require ethical assessment because only indirect literature will be included and evaluated. Furthermore, the result will be disseminated as a literature review in related journal.

3. Discussion
=============

T2DM is a complex, progressive metabolic disorder characterized by persistent hyperglycemia and associated with macrovascular and microvascular complications.^\[[@R7]\]^ SGLT2 inhibitors can not only control glycemia but also reduce body weight and hypertension, which are particularly beneficial for T2DM accompanied by cardiovascular disease.^\[[@R16]\]^ SGLT2 inhibitors are generally considered as second-line treatment after metformin in T2DM. Previous studies have reported a great ability of glycemia control and cardiovascular benefits, but only few studies aroused concern of their adverse effects. Although some of the studies began to focus on the adverse effects of SGLT2 inhibitors such as infections, osmotic diuresis, ketoacidosis, acute kidney injury, and so on,^\[[@R6]--[@R10]\]^ there is still lack of studies to evaluate the overall adverse effects about SGLT2 inhibitors. Therefore, whether SGLT2 inhibitors can safely used in clinical is still need to elucidate. There is, however, still no previous relevant systematic review regarding the overall safety of SGLT2 inhibitors as compared with placebo.

The purpose of this review is to assess the overall clinical AEs of SGLT2 inhibitors in patients with T2DM. In particular, we will identify the influence of overall clinical AEs in different class and dosages of each SGLT2 inhibitors. Overall, we will give a comprehensive picture of SGLT2 inhibitors in safety. In order to ensure the accuracy and reliability of the results, different authors will screen articles at least 3 times, respectively. We intend to use sufficient evidence to guarantee credibility for this meta-analysis. Herein, this systematic review will be relatively comprehensive study to evaluate the safety of SGLT2 inhibitors in patients with T2DM. We hope that the results from this clinical systematic review will help inform the design of clinical trials.

3.1. Strengths and limitations of this study
--------------------------------------------

This is the first comprehensive review comparing the overall clinical adverse effects of 7 different SGLT2 inhibitors by meta-analysis.The results of this systematic review will help clinicians for decision making in clinical practice.The methods of this review are state of rigorous, including comprehensive literature search, explicit inclusion and exclusion criteria, independent study selection, data extraction, quality assessment, and statistical analysis.We limit our analyses to trials of SGLT2 inhibitors as compared with placebo, and double-blinded RCTs, which may be a limitation.
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